Methods of treating B-cell proliferative disorder
Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
1. A method of treating or delaying progression of a B-cell proliferative disorder in a patient receiving a moderate CYP3A inducer, the method comprising
concomitantly administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a dose of about 320 mg twice a day, and the moderate CYP3A inducer,
wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or follicular lymphoma (FL); and
the moderate CYP3A inducer is rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital or nafcillin.
2. The method of claim 1 , wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL).
3. The method of claim 2 , wherein the moderate CYP3A inducer is rifabutin.
4. The method of claim 1 , wherein the B-cell proliferative disorder is small lymphocytic lymphoma (SLL).
5. The method of claim 1 , wherein the B-cell proliferative disorder is Waldenström macroglobulinemia (WM).
6. The method of claim 1 , wherein the B-cell proliferative disorder is mantle cell lymphoma (MCL).
7. The method of claim 1 , wherein the B-cell proliferative disorder is marginal zone lymphoma (MZL).
8. The method of claim 1 , wherein the moderate CYP3A inducer is rifabutin.
9. A method of treating or delaying progression of a B-cell proliferative disorder in a patient, the method comprising
selecting the patient who is being treated with a moderate CYP3A inducer; and
concomitantly administering to the selected patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a dose of about 320 mg twice a day, and the moderate CYP3A inducer,
wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL).
10. The method of claim 9 , wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL).
11. The method of claim 9 , wherein the B-cell proliferative disorder is small lymphocytic lymphoma (SLL).
12. The method of claim 9 , wherein the B-cell proliferative disorder is Waldenström macroglobulinemia (WM).
13. The method of claim 9 , wherein the B-cell proliferative disorder is mantle cell lymphoma (MCL).
14. The method of claim 9 , wherein the B-cell proliferative disorder is marginal zone lymphoma (MZL).
15. The method of claim 9 , wherein the moderate CYP3A inducer is rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital or nafcillin.
16. The method of claim 15 , wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL).
17. The method of claim 16 , wherein the moderate CYP3A inducer is rifabutin.
18. A method of treating or delaying progression of a B-cell proliferative disorder in a patient receiving a moderate CYP3A inducer, the method comprising
assessing the patient as to whether the patient can avoid being treated with the moderate CYP3A inducer;
selecting the patient who cannot avoid being treated with the moderate CYP3A inducer; and
concomitantly administering to the selected patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a dose of about 320 mg twice a day, and the moderate CYP3A inducer,
wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL).
19. The method of claim 18 , wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL).
20. The method of claim 18 , wherein the B-cell proliferative disorder is small lymphocytic lymphoma (SLL).
21. The method of claim 18 , wherein the B-cell proliferative disorder is Waldenström macroglobulinemia (WM).
22. The method of claim 18 , wherein the B-cell proliferative disorder is mantle cell lymphoma (MCL).
23. The method of claim 18 , wherein the B-cell proliferative disorder is marginal zone lymphoma (MZL).
24. The method of claim 18 , wherein the moderate CYP3A inducer is rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital or nafcillin.
25. The method of claim 24 , wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL).
26. He method of claim 25 , wherein the moderate CYP3A inducer is rifabutin.
27. The method of claim 9 , wherein the B-cell proliferative disorder is diffuse large B-cell lymphoma (DLBCL).
28. The method of claim 18 , wherein the B-cell proliferative disorder is diffuse large B-cell lymphoma (DLBCL).